Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952053 | 0.85 | KMT2A (0.35) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL15252478 | 0.83 | BCHE (0.40) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL21541706 | 0.80 | BUB1 (0.37) | KMT2AMEN1BCHEGPR119L3MBTL1 | |
| SCHEMBL27927848 | 0.79 | USP2 (0.39) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL15252551 | 0.79 | PDE4B (0.38) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL8288797 | 0.79 | BCHE (0.38) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL13559889 | 0.79 | BCHE (0.41) | KMT2AMEN1BCHEUSP2SMN1; SMN2 | |
| SCHEMBL5184141 | 0.78 | BCHE (0.47) | KMT2AMEN1BCHEGPR119L3MBTL1 | |
| SCHEMBL23727854 | 0.77 | MEN1 (0.41) | KMT2AMEN1BCHEGPR119FAAH | |
| SCHEMBL11911366 | 0.76 | GPR119 (0.39) | KMT2AMEN1BCHEUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4084795-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | Blue Oak Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-114929228-A | Compounds and compositions for treating CNS disorders | 布鲁奥科制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | PMP22, CHAT, ACHE | KMT2A 1869/4885MEN1 933/4885BCHE 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.